In This Issue ................................................. 1103

Meet the First Authors ..................................... 1104

Editorials

PVDOMICS Drive the Pulmonary Hypertension Field Into the Precision Medicine Era
Evangelos D. Michelakis ......................................... 1106

Monocyte Recruitment Versus Macrophage Proliferation in Atherosclerosis
Jenny E. Kanter .................................................. 1109

Considerations for Cardiac CRISPR
Kelli J. Carroll, Eric N. Olson .................................. 1111

AMP-Activated Protein Kinase γ2 to the Rescue in Ischemic Heart
Ye Ding, Ming-Hui Zou ........................................... 1113

Cardiac Cell Therapy Evolving From Complex to Straightforward: Enabling Adoption and Affordability
Keith L. March, Carl J. Pepine ................................. 1116

Commentaries on Cutting Edge Science

CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting
Christian Weber, Philipp von Hundelshausen .................. 1119

Trainee and Young Investigator Corner

Researcher, Heal Thyself?
Mary Burchett Sheppard ........................................ 1122

Leaders in Cardiovascular Science

Elizabeth Murphy: Perseverance Pays Off
Jaclyn Jansen ..................................................... 1124
News & Views

Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School
Junichi Sadoshima ................................................................. 1127

Viewpoints

Identity Crisis for Regenerative Cardiac cKit+ Cells
Onur Kanisicak, Ronald J. Vagnozzi, Jeffery D. Molkentin .................. 1130

Novel Antithrombotic Drugs on the Horizon: The Ultimate Promise to Prevent Clotting While Avoiding Bleeding
James D. McFadyen, Karlheinz Peter .......................................... 1133

The NHLBI Page

PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics

Molecular Medicine

CELF1 Mediates Connexin 43 mRNA Degradation in Dilated Cardiomyopathy
Kuei-Ting Chang, Ching-Feng Cheng, Pei-Chih King, Shin-Yi Liu, Guey-Shin Wang .......................................................... 1140

γ2-AMPK Protects Against Stress
Cao et al. page 1182

γ2-AMPK Protects Against Stress
Cao et al. page 1182

Cellular Biology

Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption
Anne Katrine Johansen, Bas Molenaar, Danielle Versteeg, Ana Rita Leitoginho, Charlotte Demkes, Bastiaan Spanjaard, Hester de Ruiter, Farhad Akbari Mogadam, Lieneke Kooijman, Lorena Zentilin, Mauro Giaccia, Eva van Rooyj .......... 1168

Integrative Physiology

Activation of γ2-AMPK Suppresses Ribosome Biogenesis and Protects Against Myocardial Ischemia/Reperfusion Injury
Yang Cao, Naveen Bojireddy, Maengjo Kim, Tao Li, Peiyong Zhai, Narayani Nagarajan, Junichi Sadoshima, Richard D. Palmter, Rong Tian .... 1182
Clinical Track

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy])


In September 2017, the average time from submission to first decision for all original research papers submitted to Circulation Research was 13 days.

On the Cover: Heart-shaped mosaic, depicting the components of the technical platform supporting MSC-based treatment in heart failure, including characterization of cell phenotype and function, as well as patient status: MSC migration device (Stellium), GMP type Lab (Cells for Cells, Chile), Clinical Campus University of los Andes, Chile, Angiogenic tube formation; patient echocardiogram, flow cytometry immunophenotype of MSCs and cardiomyocy differentiation (troponin staining). (Concept and design, Dr Maroun Khoury. Photography, Cells for Cells laboratories, Chile.) See related article, page 1192.